Early phase studies of JAK1 selective inhibitors in rheumatoid arthritis

Area of Science:

• Immunology and Rheumatology
• Pharmacology and Drug Development

Background:

• Early Janus kinase (JAK) inhibitors for rheumatoid arthritis (RA) targeted multiple JAK molecules, offering broad cytokine inhibition but potentially increasing toxicity.
• Development of selective JAK inhibitors aims to enhance the safety-efficacy profile and improve drug maintenance in RA treatment.

Purpose of the Study:

• To evaluate the efficacy and adverse effects of selective JAK1 inhibitors, including upadacitinib, filgotinib, and itacitinib.
• To define the potential role of these selective JAK1 inhibitors in treating inflammatory and autoimmune diseases, particularly RA.

Main Methods:

• Initiation of early phase (Phase I-II) clinical trials for selective JAK1 inhibitors.
• Assessment of efficacy, safety, and tolerability in RA patient populations, including refractory cases.
• Dose selection for Phase III trials based on benefit-risk profiles.

Main Results:

• Early phase studies of upadacitinib and filgotinib demonstrated significant efficacy and favorable safety profiles in RA patients.
• These findings supported dose selection for subsequent Phase III trials, indicating a balanced benefit-risk profile.
• Itacitinib also showed good efficacy and safety in Phase II RA trials but is primarily developed for hematologic and oncologic conditions.

Conclusions:

• Selective JAK1 inhibitors, such as upadacitinib and filgotinib, represent a promising therapeutic option for refractory RA.
• Early clinical data support their potential to improve treatment outcomes while managing safety concerns.
• Further evaluation in Phase III trials is crucial for establishing their definitive role in autoimmune disease management.